MedTrace Logo

A Study to Evaluate the Intramuscular Administration of Scopolamine

NCT04314713 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-02-19

Study results available
· View outcomes & findings →

Summary

To characterize the safety and tolerability profile of ascending doses of scopolamine hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection. And characterize the pharmacokinetics (PK) of ascending doses of Scopolamine HBT administered by IM injection

Conditions

  • Medical Countermeasures
  • Organophosphate Poisoning

Interventions

DRUG

Scopolamine Hydrobromide Trihydrate

Scopolamine Hydrobromide Trihydrate Intramuscular Injection

Sponsors & Collaborators

  • Battelle Memorial Institute

    lead OTHER

Principal Investigators

  • Paolo DePetrillo, MD · Pharmaron

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2021-04-06
Completion
2021-05-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314713 on ClinicalTrials.gov